Evidence map›Paper›PMID 41457913›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

ADAMTS9-AS2 Disrupts Docetaxel-Resistance in Castration-Resistant Prostate Cancer via Stemness Suppression and Ferroptosis Induction.

Ji Liu, Yan Gao, Yadong Guo, Junfeng Zhang, Wentao Zhang, Zhuoran Gu, Haotian Chen, Chengqi Jin, Peng Luo, Shiyu Mao and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Human mutation · 2026
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ji LiuDepartment of Urology, School of Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai, P. R. China.ORCID https://orcid.org/0000-0002-8869-9463
Yan GaoSchool of Chemical Science and Engineering, Department of Laboratory Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai, P. R. China.
Yadong GuoDepartment of Urology, School of Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai, P. R. China.
Junfeng ZhangDepartment of Urology, School of Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai, P. R. China.
Wentao ZhangDepartment of Urology, School of Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai, P. R. China.
Zhuoran GuDepartment of Urology, School of Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai, P. R. China.
Haotian ChenDepartment of Urology, School of Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai, P. R. China.
Chengqi JinDepartment of Urology, School of Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai, P. R. China.
Peng LuoThe Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, P. R. China.
Shiyu MaoDepartment of Urology, School of Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai, P. R. China.
Yajuan HaoDepartment of Urology, School of Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai, P. R. China.
Shuo ShiSchool of Chemical Science and Engineering, Department of Laboratory Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai, P. R. China.ORCID https://orcid.org/0000-0003-4387-3445
Xudong YaoDepartment of Urology, School of Medicine, Shanghai Tenth People's Hospital, Tongji University, Shanghai, P. R. China.ORCID https://orcid.org/0000-0001-7234-3940

Funding

Experimental Animal Fund of Shanghai Science and Technology Commission #22140903800MJR Young Scientist Research Fund Grant MJR202310015National Natural Science Foundation of China Major Project T2495262National Natural Science Foundation of China, Youth Project #82101838National Natural Science Foundation of China, Youth Project #82203367National Natural Science Foundation of China, Youth Project #82302304National Natural Science Foundation of China, Youth Project #82503841Tongji University Medicine-X Interdisciplinary Research Initiative 2025-0553-YB-02
6 · The paper itself

Abstract

Castration-resistant prostate cancer (CRPC) chemotherapy resistance remained a significant clinical challenge. Prostate tumor stem cells (PCSCs) played a crucial role in chemotherapy resistance, but the underlying mechanisms were not fully understood. This study investigated how ADAMTS9-AS2 reduced chemotherapy resistance in CRPC through a dual mechanism and explored the potential of polymeric materials targeting PCSCs and enhancing chemotherapy sensitivity. Key regulatory molecules of PCSCs were identified through mRNAsi-based multi-center patient cohorts. The effect of ADAMTS9-AS2 on reducing docetaxel resistance in CRPC was assessed, and its mechanisms were further explored using in vitro and in vivo experiments. Finally, polymeric materials containing TGF-β inhibitor, ferroptosis inducer, and miR-182-5p inhibitor were used to target PCSCs to improve chemotherapy sensitivity. ADAMTS9-AS2 reduced CRPC chemotherapy resistance through dual mechanisms: (1) regulating FOXF2/TGF-β2 axis to suppress PCSCs stemness; (2) encoding a short peptide that competitively retained more SLC7A11 in the cytoplasm than on the cytomembrane, thus promoting ferroptosis. Furthermore, polymeric materials targeting PCSCs significantly enhanced docetaxel sensitivity and inhibited tumor progression. ADAMTS9-AS2 delayed docetaxel resistance by suppressing CRPC stemness and inducing ferroptosis. The use of polymeric materials targeting PCSCs offered a novel strategy to overcome CRPC chemotherapy resistance.

Indexed as

ADAMTS ProteinsDocetaxelDrug Resistance, NeoplasmFerroptosisNeoplastic Stem CellsProstatic Neoplasms, Castration-ResistantADAM ProteinsAnimalsAntineoplastic AgentsCell Line, TumorHumansMaleMembrane ProteinsMiceMice, NudeADAM9 protein, humanADAM ProteinsADAMTS ProteinsAntineoplastic AgentsDocetaxelMembrane Proteinscancer stem cellsdocetaxel resistanceferroptosisnanomaterialprostate cancer

Identifiers

PMID41457913
PMCPMC12915152

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.